Creating a Global Company
Key Milestones in US
FY22
•
Launched Winlevi® (clascoterone cream 1%) for topical treatment of acne vulgaris
SUN
PHARMA
FY21
FY20
FY19
FY18
FY17
FY13
FY10
FY98
•
Presented long term clinical data for Ilumya & other clinical insights for Odomzo & Levulan
at American Academy of Dermatology Conference
• Presented Pre-clinical data for GL0034 (GLP-1R agonist) at American Diabetes Association
Conference
Launched Cequa in US
• Launched Absorica LD in US in Feb-2020
• Launched Ilumya & Yonsa in US
• Received USFDA approval for Cequa
• Launched Xelpros in US
• Launched Ready-to-Infuse INFUGEM™M
• Launched Odomzo in US
• US FDA approval for Ilumya
.
Tildrakizumab filing in US & Europe
• Acquired Ocular Technologies giving access to Cequa, a product for dry eyes.
• Acquired Odomzo- branded oncology product from Novartis
• Acquired DUSA - Entry in branded specialty market
.
.
Acquired Taro Pharma - Entry into US dermatology market
• Entry in US through Caraco acquisition
21View entire presentation